TITLE

Salvage treatment with upfront melphalan 100 mg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma

AUTHOR(S)
Krejci, Marta; Adam, Zdenek; Buchler, Tomas; Krivanova, Andrea; Pour, Ludek; Zahradova, Lenka; Holanek, Michal; Sandecka, Viera; Mayer, Jiri; Vorlicek, Jiri; Hajek, Roman
PUB. DATE
May 2010
SOURCE
Annals of Hematology;May2010, Vol. 89 Issue 5, p483
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Patients (pts) with fulminant progression (FPG) of multiple myeloma (MM) after autologous stem cell transplantation (ASCT) have poor prognosis. Pancytopenia, extramedullary disease, and/or renal impairment are often present, and treatment options are limited. We have retrospectively evaluated 31 pts with FPG of MM after ASCT who were treated upfront salvage therapy with melphalan 100 mg/m2 (MEL 100) followed by PBSC support and consolidation therapy using regimens containing thalidomide ( n = 16) or bortezomib ( n = 15). The overall response rate (ORR) was 58% (18/31). After MEL 100, one patient achieved complete remission (3%), 26% of pts very good partial remission, 29% of pts partial remission, and 42% of pts stable disease. Progression within 3 months after MEL 100 occurred in 35% of pts. The median follow-up from MEL 100 was 8 months. The median TTP was 5 months (range, 2–15 months), and the median OS was 8 months (range, 3–23 months). There were no treatment-related deaths. In fulminant progression of MM, upfront MEL 100 is a safe salvage regimen with good response rate (ORR, 58%). Treatment with upfront MEL 100 followed by a thalidomide- or bortezomib-based regimen can prolong overall survival to more than 12 months in 33% of pts with fulminant progression of MM.
ACCESSION #
48600671

 

Related Articles

  • Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: A retrospective medical records review. Weide, Rudolf; Köppler, Hubert; Antràs, Lucia; Smith, Michael; MPH, Eva Chang; Green, Jesse; Wintfeld2,, Neil; Neary, Maureen P.; Duh, Mei Sheng // Journal of Cancer Research & Therapeutics;Jan-Mar2010, Vol. 6 Issue 1, p31 

    Aims: This retrospective study investigated the rates of renal impairment in patients with multiple myeloma treated with zoledronic acid and ibandronate. Materials and Methods: We retrospectively reviewed medical records in a German oncology clinic, from May 2001 to December 2005. Creatinine...

  • Cards spell out duties of 4 nurses.  // Same-Day Surgery;Sep2008, Vol. 32 Issue 9, p96 

    The article focuses on the cards that are developed to explain the role of each of four nurses who handle malignant hyperthermia (MH) resuscitation at Ponte Vedra Plastic Surgery in Florida.

  • Isoflurane.  // Reactions Weekly;Sep2015, Vol. 1569 Issue 1, p137 

    The article presents a case study of a 13-year-old boy who developed malignant hyperpyrexia after isoflurane treatment.

  • FIBROMUSCULAR DYSPLASIA OF THE RENAL ARTERY: A CASE REPORT. Pessina, A. C.; Pagnan, Antonio; Visona, Adriana; Feltrin, Giampietro; Thiene, Gaetano; Pauletto, Pauolo; Dal Palu, Cesare // Vascular Surgery;Jan/Feb1982, Vol. 16 Issue 1, p66 

    We describe the case of a woman who developed in only 1 year focal fibromuscular dysplasia stenosing the lumen of the renal artery by 70%. The clinical implications of such findings are discussed.

  • Comparison of unilateral renal artery embolization versus bilateral for treatment of severe refractory hypertension in hemodialysis patients. Zhiguo Mao; Chaoyang Ye; Changlin Mei; Xuezhi Zhao; Yuqiang Zhang; Chenggang Xu; Linlin Sun; Wu, Jun; Huimin Li; Weihua Dong; Sheng Dong // World Journal of Urology;Oct2009, Vol. 27 Issue 5, p679 

    Hypertension in ESRD patients is common, and often refractory to common medical interventions. Bilateral renal embolization (BRE) is an alternative to nephrectomy in treating severe refractory hypertension in hemodialysis patients, but has drawbacks in residual renal function preservation and...

  • Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role. D’Arena, Giovanni; Rossi, Giovanni; Laurenti, Luca; Statuto, Teodora; D’Auria, Fiorella; Valvano, Luciana; Simeon, Vittorio; Giudice, Aldo; Innocenti, Idanna; De Feo, Vincenzo; Filosa, Rosanna; Musto, Pellegrino; D'Arena, Giovanni; D'Auria, Fiorella // Journal of Immunology Research;7/14/2016, p1 

    The frequency and function of regulatory T-cells (Tregs) in multiple myeloma (MM) are still matter of debate. The percentage and absolute number of circulating Tregs (CD4(+)CD25(+high  density)CD127(-/low  density)) from 39 patients with untreated MM and 44 patients...

  • Manufacturer's response to Bilmen and Gillies' manuscript entitled "Clarifying the role of activated charcoal filters in preparing an anaesthetic workstation for malignant hyperthermia-susceptible patients". Orr, J.; Sakata, D. // Anaesthesia & Intensive Care;Nov2014, Vol. 42 Issue 6, p801 

    A letter to the editor is presented in response to the article "Clarifying the Role of Activated Charcoal Filters in Preparing an Anaesthetic Workstation for Malignant Hyperthermia-Susceptible Patients," by J. G. Bilmen and R. I. Gillies which appeared in a previous 2014 issue.

  • Malignant Hyperthermia Susceptibility and the Trauma Patient. Sheehan, Jacqueline A. // Military Medicine;Jun2005, Vol. 170 Issue 6, p510 

    Assorted casualties are expected from combat. Triage of the wounded may result in some going directly to surgery. Although every minute is essential, anesthetic care of these trauma patients must adhere to all established standards of care. A timely preoperative assessment must include...

  • Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Imagawa, A.; Hanafusa, T.; Uchigata, Y.; Kanatsuka, A.; Kawasaki, E.; Kobayashi, T.; Shimada, A.; Shimizu, I.; Maruyama, T.; Makino, H. // Diabetologia;Feb2005, Vol. 48 Issue 2, p294 

    Aims/hypothesis: Fulminant type 1 diabetes, which is characterised by a markedly acute onset of diabetes and an absence of islet-related autoantibodies, accounts for 20% of type 1 diabetes in Japan. We aimed to clarify the contribution of the HLA subtype to fulminant type 1 diabetes in Japanese....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics